1. The Guselkumab group demonstrated significantly greater clinical and endoscopic responses versus placebo. 2. Serious adverse events were comparable, with...

1. The majority of treatment-related adverse events were mild-to-moderate gastrointestinal events with no reported deaths. 2. Amycretin resulted in significant...

1. Hemoglobin response was significantly greater in the treatment group compared to placebo. 2. Majority of adverse events were mild...

1. The 5-year recurrence-free survival was comparable with ablation and without ablation. 2. Adverse events were comparable in both groups,...

1. Recurrent ischemic stroke rates were significantly reduced in patients who started DOAC within 4 days of an acute ischemic...

1. Progression-free survival was significantly greater in retifanlimab compared to placebo. 2. Serious and grade 3 or more adverse events...

1. Progression-free and overall survival were greater in relacorilant plus nab-paclitaxel compared to nab-paclitaxel alone. 2. The rate of adverse...

1. ANGPTL4 inhibition decreased triglyceride and remnant cholesterol levels by over 50%. 2. MAR001 was well-tolerated with no significant treatment-related...

1. Abbreviated MRI detected three times as many invasive cancers compared with ABUS. 2. Contrast-enhanced mammography detected a greater number...

1. Median overall survival was 3.1 months greater in the nivolumab plus ipilimumab group. 2. Grade 3-4 treatment-related adverse events...